filgotinib | Filgotinib

Keyword	CPC	PCC	Volume	Score	Length of keyword
filgotinib	1.46	0.9	8382	26	10

Keyword	CPC	PCC	Volume	Score
filgotinib	0.98	0.4	865	70
filgotinib spc	1.31	1	1790	84
filgotinib bnf	0.96	0.5	6947	66
filgotinib ulcerative colitis	1.06	0.4	799	42
filgotinib ema	0.74	0.3	2756	99
filgotinib maleate	1.35	0.7	3293	50
filgotinib fda	0.91	0.9	351	68
filgotinib smpc	0.57	0.1	3378	94
filgotinib ibd	1.86	0.6	6032	73
filgotinib side effects	0.49	0.6	3664	29
filgotinib fachinformation	1.14	0.1	439	59
filgotinib approval	0.61	0.8	8629	98
filgotinib jyseleca	0.78	0.4	5054	77
filgotinib fda approval	0.22	0.5	1029	81
filgotinib nebenwirkungen	1.82	0.3	9339	49

Search Results related to filgotinib on Search Engine

Filgotinib - Wikipedia
wikipedia.org

https://en.m.wikipedia.org/wiki/Filgotinib

WEBFilgotinib may be used as monotherapy or in combination with methotrexate (MTX). Mechanism of action. Filgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively, similar to already marketed upadacitinib.

DA: 9 PA: 64 MOZ Rank: 54

Filgotinib: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB14845

WEBMay 20, 2019 · Filgotinib is indicated for the treatment of active moderate to severe rheumatoid arthritis alone or in combination with methotrexate. 10 Filgotinib is currently reserved for patients who are unable to tolerate or who have not responded adequately to one or more disease-modifying anti-rheumatic drugs (DMARDS). 10.

DA: 90 PA: 34 MOZ Rank: 85

Filgotinib | Side-effects, uses, time to work - Versus Arthritis
versusarthritis.org

https://www.versusarthritis.org/about-arthritis/treatments/drugs/filgotinib/

WEBFilgotinib is a drug used to treat rheumatoid arthritis. Find out more about how it works, how it's taken, and the potential risks and benefits.

DA: 3 PA: 24 MOZ Rank: 17

Filgotinib as induction and maintenance therapy for ulcerative …
thelancet.com

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00666-8/fulltext

WEBJun 3, 2021 · Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial - The Lancet. Articles | Volume 397, ISSUE 10292, P2372-2384, June 19, …

DA: 51 PA: 59 MOZ Rank: 44

Filgotinib: A Clinical Pharmacology Review - PMC - National …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249714/

WEBMay 31, 2022 · Filgotinib (GS-6034, formerly GLPG0634; Jyseleca ®) is an oral, preferential Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 modulates a subset of proinflammatory cytokines within the JAK–signal transducer and activator of transcription pathway, which differ from those inhibited by JAK2 or JAK3.

DA: 69 PA: 33 MOZ Rank: 52

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use - PMC
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613087/

WEBJul 25, 2021 · Filgotinib (Jyseleca ®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). In phase 3 trials, once-daily ...

DA: 94 PA: 73 MOZ Rank: 63

Filgotinib, a novel JAK1-preferential inhibitor for the treatment of
oup.com

https://academic.oup.com/mr/article/32/1/1/6458384

WEBApr 15, 2021 · Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Yoshiya Tanaka. , Arthur Kavanaugh. , Jason Wicklund. , Iain B McInnes. Modern Rheumatology, Volume 32, Issue 1, January 2022, Pages 1–11, https://doi.org/10.1080/14397595.2021.1902617. Published: …

DA: 68 PA: 65 MOZ Rank: 45

Filgotinib: First Approval - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33237566/

WEBAbstract. Filgotinib (Jyseleca ®) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and …

DA: 32 PA: 96 MOZ Rank: 67

Filgotinib: First Approval - PMC - National Center for …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858213/

WEBNov 25, 2020 · Filgotinib (Jyseleca ®) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.

DA: 24 PA: 48 MOZ Rank: 47

Jyseleca | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca

WEBJul 24, 2020 · filgotinib. Medicine Human. Overview. Jyseleca is a medicine for treating adults with: moderate to severe rheumatoid arthritis, a disease in which the immune system (the body’s natural defences) attacks healthy tissue causing inflammation and pain in joints.

DA: 65 PA: 13 MOZ Rank: 65